M.E.L. van der Burg

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

Felix E. de Jongh, Ruben N. van Veen, S J Veltman et al. · British Journal of Cancer · 2003 · 267 citations · Full text

Medicine, Oncology, Pharmacology +17

RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA

J.P. Neijt, M.E.L. van der Burg, R. Vriesendorp et al. · The Lancet · 1984 · 250 citations · Full text

Medicine, Gynecology, Oncology +12

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

P.M.L.H. Vencken, Mieke Kriege, D. Hoogwerf et al. · Annals of Oncology · 2011 · 215 citations · Full text

Medicine, Gynecology, Oncology +13

Long-term survival in ovarian cancer

J.P. Neijt, W.W. ten Bokkel Huinink, M.E.L. van der Burg et al. · European Journal of Cancer and Clinical Oncology · 1991 · 213 citations

Medicine, Oncology, Surgery +14

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Matti Aapro, F.H. van Wijk, Giorgio Bolis et al. · Annals of Oncology · 2003 · 200 citations · Full text

Medicine, Gynecology, Oncology +8